Retinitis punctata albescens (RPA) is an infrequently occurring form of autosomal recessive (and rarely dominant) retinal dystrophy featuring early-onset severe night blindness and tiny, dotlike, white deposits in the fundus. RPA is associated mostly with mutations in RLBP1 and occasionally in RHO, RDS, and RDH5. In this study, mutations were sought in RLBP1, which encodes the retinol binding protein CRALBP in patients with typical RPA. METHODS. Clinical investigation included funduscopy, visual field testing, electroretinogram recording, and adaptometry. The 7 coding exons (3-9) of RLBP1 and the 15th (last) exon of ABDH2 were PCR amplified and sequenced. Long-distance PCR and cloning of genomic DNA were performed to characterize the deletion. RESULTS. The study involved a 24-year-old Moroccan patient with typical RPA, born of first-cousin parents. He carried a 7.36-kb homozygous deletion encompassing the last 3 exons of RLBP1 (7, 8, and 9) and part of the intergenic region between RLBP1 and ABHD2, which lies downstream of RLBP1. This deletion abolishes the retinal binding site of CRALBP. The telomeric breakpoint of the deletion (in RLBP1 intron 6) is embedded in an Alu element, whereas the centromeric breakpoint (in the intergenic region) lies between two Alu elements placed in the opposite orientation. CONCLUSIONS. Because of the high density of Alu elements in RLBP1, a systematic search should be made for deletions in this gene when one or both alleles lack point mutations, in the case of RPA or flecked retinal dystrophy. (Invest Ophthalmol Vis Sci. 2006;47:4719 -4724) DOI:10.1167/iovs.05-1488 T he cellular retinaldehyde-binding protein (CRALBP) belongs to the CRAL-TRIO family whose members bind lipid ligands in a hydrophobic domain. It binds the vitamin A derivatives 11-cis retinol and 11-cis retinal, with more affinity for the aldehyde form. As such, CRALBP is a key actor in the visual cycle, the multistep process that starts with all-trans retinal, the product of the activated rhodopsin, and ends with 11-cis retinal, the chromophore that binds opsins to regenerate rhodopsin and cone photopigments. CRALBP is found in the retina, specifically in the retinal pigment epithelium and the Müller glial cells, where it accelerates the rate of the isomerization to 11-cis retinol.
T he cellular retinaldehyde-binding protein (CRALBP) belongs to the CRAL-TRIO family whose members bind lipid ligands in a hydrophobic domain. It binds the vitamin A derivatives 11-cis retinol and 11-cis retinal, with more affinity for the aldehyde form. As such, CRALBP is a key actor in the visual cycle, the multistep process that starts with all-trans retinal, the product of the activated rhodopsin, and ends with 11-cis retinal, the chromophore that binds opsins to regenerate rhodopsin and cone photopigments. CRALBP is found in the retina, specifically in the retinal pigment epithelium and the Müller glial cells, where it accelerates the rate of the isomerization to 11-cis retinol. 1 Accordingly, mice lacking CRALBP have considerably delayed dark adaptation. 2 CRALBP is also found in the ciliary epithelium, iris, cornea, pineal gland, and in some oligodendrocytes of the optic nerve and brain, 3, 4 where its function remains unclear.
In human, mutations in RLBP1, the gene encoding CRALBP, have been found in various types of retinal dystrophiesnamely, retinitis punctata albescens (RPA) in most cases, [5] [6] [7] [8] autosomal recessive retinitis pigmentosa, 9 Bothnia dystrophy, 10 -12 Newfoundland rod-cone dystrophy, 13 and fundus albipunctatus. 14 Although there is an apparent phenotypic heterogeneity, the clinical presentation is in fact quite well characterized and helps in directing the molecular diagnosis that prompts the search for RLBP1 mutations. Clinical features are night blindness from infancy with elevated threshold in adaptometry, progressive loss in visual acuity due to macular degeneration, the presence of tiny white deposits and patches of atrophy in peripheral retina contrasting with the absence or scarcity of pigment deposits, and predominant rod over cone involvement. This condition is in fact appearing as a subtype of autosomal recessive retinitis pigmentosa, leading after several decades to severe visual loss.
In this study, we describe a patient with typical RPA who carries a homozygous 7.36-kb deletion that includes the last 3 exons of RLBP1. We show that this deletion occurred in a portion of the genome that is rich in Alu sequences.
MATERIALS AND METHODS

Clinical Investigations
A standard ophthalmic examination (refractometry, visual acuity, slitlamp examination, applanation tonometry, and funduscopy) was performed. Fluorescein angiography was performed, and visual fields were tested with a Goldmann perimeter using targets V 4e , IV 4e , and II 4e . A full-field ERG was performed according to ISCEV (International Society for Clinical Electrophysiology of Vision) recommendations. Dark adaptometry was performed with a Goldmann-Weekers apparatus and a test seen with an angle of 11°, placed at a distance of 30 cm from the eyes and centered on the point of fixation. Patients were light adapted for 5 minutes at 2100 asb before dark adaptation for 30 minutes. 
Mutation Screening
PCR Reactions. Informed consent of the patient and of his unaffected brother were obtained, in accordance with the Declaration of Helsinki, and the genomic DNA was extracted by using a standard salting out procedure. 15 The seven coding exons 3 through 9 of RLBP1 (GenBank accession no. NM_000326; http://www.ncbi.nlm.nih.gov/ Genbank; provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD) and the 15th (last) exon of ABDH2 (NM_007011) were amplified in a 25-L volume containing 3 mM MgCl 2 , 200 M dNTPs, 10 picomoles of forward and reverse primers (Table 1) , 100 to 150 ng of DNA, and 0.5 U of Taq DNA polymerase (Promega Madison, WI) in the appropriate buffer. After the denaturation step at 94°C for 5 minutes, the amplification was performed for 35 cycles at 94°C for 30 seconds, at the appropriate annealing temperature for 30 seconds (Table 1) , and at 72°C for 1 minute, ending with a final extension step at 72°C for 10 minutes.
Amplicons were run on 2% agarose gels in 1ϫ TAE (Tris-acetate-EDTA) buffer to check for the quality and specificity of the PCR reaction. The same PCR program was applied to search for the deletion in 50 control Moroccan individuals, with primers 3F and 6R (Table 1) .
To determine the 3Ј and 5Ј sequences flanking the deletion, we used long-distance PCR with primers 7F and 7R (Table 1) to amplify a 1.7-kb fragment (instead of the 8.695-kb wild-type fragment) in a 20-L volume containing 500 M dNTPs, 6 picomoles of forward and reverse primers, 100 to 150 ng of DNA, and 1.5 U of PCR mixture (Expand Long Template; Roche, Basel, Switzerland) in the appropriate buffer. After the denaturation step at 95°C for 2 minutes, the amplification was performed for 35 cycles at 95°C for 30 seconds, 55°C for 30 seconds, and 68°C for 4 minutes, ending with a final extension step at 68°C for 10 minutes. Amplicons were analyzed on 1% agarose gels, TA-cloned (Invitrogen, Groningen, The Netherlands) and PCR-screened.
Sequencing. Clones and purified PCR products (QIAquick PCR purification Kit; Qiagen, Hilden, Germany) were sequenced in both directions (BigDye Terminator Cycle Sequencing Ready Reaction kit ver. 1.1; Prism 310 or 3130 capillary sequencer; Applied Biosystems, Foster City, CA). Sample sequences were aligned to the wild-type ones and analyzed with the collection and sequence analysis software package (Applied Biosystems).
RESULTS
Case Report
The patient was a 24-year-old Moroccan man, born of first-cousin parents. He became aware of night blindness at the age of 6. At age 12, he noticed some difficulties in far sight. At the time of the examination, he had severe reading impairment and photophobia, but he did not mention difficulties in moving about by himself outside. His visual acuity was 10/200 OD with ϩ1.50(Ϫ1.25; 75°) and counting fingers OS with ϩ2.25(Ϫ1.25; 120°). The fundus showed many tiny white dots around the fovea and beyond the vascular arcades (Figs. 1B, 1C ), whereas that of his unaffected brother was normal (Fig. 1A) . The retinal vessels were slightly narrowed. There were no pigment deposits, and the optic discs were not pale. Fluorescein angiography showed a cystoid macular edema (Fig. 1D) . In Goldmann perimetry, there was some degree of peripheral visual field loss that predominated in the right eye, and an absolute central scotoma that was larger in the left eye (Figs. 1E, 1F) . A full-field electroretinogram with the patient wearing contact lenses did not detect any rod responses, but highly attenuated mixed rod-cone responses and pure cone responses at 30-Hz flickers were still recordable (Fig. 1G) . Dark adaptometry 1H ).
Mutation
The observation of a patient with RPA prompted us to screen the RLBP1 gene. No mutations were detected in the first four coding exons (3-6). However, exons 7, 8, and 9 could not be amplified in the patient, whereas they could in the unaffected patient's brother (not shown), suggesting that the patient carried a large homozygous deletion. PCR-based DNA walking on 20 kb downstream of RLBP1 exon 6 indicated that the deletion started in RLBP1 intron 6 and ended downstream of the ABHD2 gene, which lies 14.1 kb downstream of RLBP1 in the opposite orientation (Fig. 2) . Using long-distance PCR, we found a 7361-bp deletion associated with the insertion of a C (Fig. 2) . This deletion was absent in 100 control Moroccan chromosomes (not shown). It spans the last 3 exons of RLBP1 and part of the intergenic region situated between RLBP1 and ABHD2 which encodes the androgen regulated a/b hydrolase II (Fig 2) . A search for intragenic homologous sequences revealed that the region is rich in Alu repeats oriented in both directions. We found that the telomeric breakpoint of the deletion (in RLBP1 intron 6) is embedded in one Alu element, including the 26 nucleotide core sequence containing the When only one mutation is reported, it means that the patient is homozygous. In the Disease Type column, the numbers in brackets refer to articles cited in the references. ARRP, autosomal recessive retinitis pigmentosa; BD, Bothnia dystrophy; CF, counting fingers; FA, fundus albipunctatus; LP, light perception; ND, not done; NFRCD, Newfoundland rod-cone dystrophy, RPA, Retinitis punctata albescens.
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chi-like recombinogenic pentanucleotide CCAGC, whereas the centromeric breakpoint (in the intergenic region) lies between two Alu elements placed in the opposite orientation (Figs. 2,  3A) . Fifty-nine nucleotides upstream of the centromeric breakpoint in the deleted fragment are four copies of the recombinogenic pentanucleotide (Fig. 3A) . Alignment of the mutated sequence with that at each breakpoint shows a homology on three nucleotides around the deletion (Fig. 3B) .
DISCUSSION
To date, there have been seven pathogenic amino acid changes in six codons reported in RLBP1 and three truncating mutations, including two frameshifts in exon 4, leading to premature stop codons in exon 5 and one in exon 9 that extends the CRALBP protein from 317 to 326 amino acids (Fig. 4) . In our patient, the deletion led to the loss of the C-terminal 142 (over 317) amino acids of CRALBP (i.e., 45% of the protein). Because the deletion involves the last exons of the gene, it is possible that downstream cryptic splice sites are recruited in the intergenic sequence, with the selection of alternative exons, thus resulting in the addition of illegitimate amino acids. Further studies using antibodies against the N-terminal portion of the protein would be necessary to address this question. In any case, the deletion causes the loss of the retinal binding site, which extends from residues 165 to 255, 16 as is true of two of the previously reported truncating mutations.
So far, the phenotypes described in the literature do not show genotype-phenotype correlations that would have distinguished between patients carrying either amino acid changes or protein truncations ( Table 2 ). The phenotype observed in our patient is typical of RPA. The severity of the disease appears to be in the average range. As is usually found in young adults with RPA, signs of photoreceptor loss were not prominent in the fundus, retinal vessels being only moderately attenuated, and, except for the tiny white deposits, there were no lesions in the retinal periphery. The major symptom of the patient was the dramatic decrease in visual acuity, which was due to the macular cystoid edema, a frequent complication in RPA.
Unequal homologous recombination of Alu sequences 17 is a frequent cause of deletions and insertions in the human genome, with some cases reported in X-linked retinoschisis, another type of hereditary retinal dystrophy. 18 The Alu elements are approximately 300 bp in length and make up approximately 10% of the human genome. 19 In the case of RLBP1, there are 10 Alu elements from exon 6 to 10 kb downstream, representing 29% of the DNA in this region, much higher than that of the 10% of the whole human genome. The presence of these elements at such a high density is therefore likely to be the primary cause of the deletion. The very short homology (Fig. 3B) between the breakpoint regions may have played a role in the deletion process.
Although this is the first report of a large deletion in this gene, the high density of Alu elements in this region offers multiple possibilities of recombination. Hence, other deletions could be encountered in RLBP1. Therefore, we suggest that the search for deletions be systematically tested in RLBP1 when one or both alleles do not show a point mutation in the case of a suggestive phenotype such as RPA or flecked retinal dystrophy.
